Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Infantile spasm: Overview PART 06: Market landscape • Global infantile spasms therapeutics market • Five forces analysis PART 07: Market segmentation by dosage form • Solid • Liquid PART 08: Market segmentation by ROA • Oral • Parenteral PART 09: Geographical segmentation • Infantile spasms therapeutics market in Americas • Infantile spasms therapeutics market in EMEA • Infantile spasms therapeutics market in APAC PART 10: Market drivers • Major drugs launch expected in 2017-2021 • Growing scientific advancements in diagnostics • Special regulatory designations PART 11: Impact of drivers PART 12: Market challenges • Growing usage of seizure management devices, a threat to drug therapies • Limited patient population • Moderate pipeline PART 13: Impact of drivers and challenges PART 14: Market trends • Development of devices and smartphone apps to detect seizures and track medications • Alternate drugs fill the gap • Reformulation of marketed drugs PART 15: Vendor landscape • Competitive scenario • Other prominent vendors PART 16: Key vendor analysis • H. Lundbeck • Mallinckrodt Pharmaceuticals • INSYS Therapeutics PART 17: Appendix • List of abbreviations PART 18: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Snapshot of global infantile spasms therapeutics market 2016 Exhibit 03: Market overview of global infantile spasms therapeutics market Exhibit 04: Opportunity analysis in developed and emerging markets Exhibit 05: Global infantile spasm therapeutics market 2016-2021 ($ millions) Exhibit 06: Approved infantile spasms therapeutics Exhibit 07: Key customer segments of global infantile spasms therapeutics market Exhibit 08: Five forces analysis Exhibit 09: Segmentation of global infantile spasms therapeutics market by dosage form Exhibit 10: Segmentation of global infantile spasms therapeutics market by ROA Exhibit 11: Market share of global infantile spasms therapeutics market by ROA Exhibit 12: Snapshot of global infantile spasms therapeutics market by geography Exhibit 13: Global infantile spasms therapeutics market segmentation by geography 2016-2021 ($ millions) Exhibit 14: Overview of infantile spasms therapeutics disease market in Americas Exhibit 15: Market scenario in Americas Exhibit 16: Healthcare system in US: Before and after reforms in ACA Exhibit 17: Orphan drug development and regulatory challenges in America Exhibit 18: Incentives provided for orphan drugs by US regulation Exhibit 19: Infantile spasms therapeutics disease market in Americas 2016-2021 ($ millions) Exhibit 20: Overview of infantile spasms therapeutics market in EMEA Exhibit 21: Percentage share of epilepsy drugs market in EMEA by geography 2015 Exhibit 22: Market scenario in EMEA Exhibit 23: Incentives provided for orphan drugs by EU regulation Exhibit 24: Infantile spasms therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 25: Overview of infantile spasms market in APAC Exhibit 26: Market scenario in APAC Exhibit 27: Incentives provided for orphan drugs by Japanese regulation Exhibit 28: Incentives provided for orphan drugs by Australian regulation Exhibit 29: Infantile spasms therapeutics market in APAC 2016-2021 ($ millions) Exhibit 30: CP-115 target indications Exhibit 31: Clinical trial information for cannabidiol Exhibit 32: Impact of drivers Exhibit 33: Pipeline for infantile spasms therapeutics market Exhibit 34: Pipeline molecules being developed for the treatment of infantile spasms disease Exhibit 35: Impact of drivers and challenges Exhibit 36: Impact of trends in global infantile spasms therapeutics market Exhibit 37: Competitive structure analysis of global infantile spasm therapeutics market 2016 Exhibit 38: Geographical presence of key vendors Exhibit 39: H. Lundbeck: Key highlights Exhibit 40: H. Lundbeck: Strength assessment Exhibit 41: H. Lundbeck: Strategy assessment Exhibit 42: H. Lundbeck: Opportunity assessment Exhibit 43: Mallinckrodt Pharmaceuticals: Profile Exhibit 44: Mallinckrodt Pharmaceuticals: Strength assessment Exhibit 45: Mallinckrodt Pharmaceuticals: Strategy assessment Exhibit 46: Mallinckrodt Pharmaceuticals: Opportunity assessment Exhibit 47: INSYS Therapeutics: Key highlights Exhibit 48: INSYS Therapeutics: Strength assessment Exhibit 49: INSYS Therapeutics: Strategy assessment Exhibit 50: INSYS Therapeutics: Opportunity assessment

H. Lundbeck, Mallinckrodt Pharmaceuticals, INSYS Therapeutics, Anavex Life Sciences, Catalyst Pharmaceuticals, GW Pharmaceuticals, ORPHELIA Pharma, Retrophin, Valerion Therapeutics.